Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) Non Operating Income (2016 - 2025)

Historic Non Operating Income for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to $670734.0.

  • BioRestorative Therapies' Non Operating Income fell 4389.87% to $670734.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 2448.3%. This contributed to the annual value of $2.6 million for FY2024, which is 4637.15% down from last year.
  • Latest data reveals that BioRestorative Therapies reported Non Operating Income of $670734.0 as of Q3 2025, which was down 4389.87% from $649024.0 recorded in Q2 2025.
  • Over the past 5 years, BioRestorative Therapies' Non Operating Income peaked at $7.9 million during Q3 2023, and registered a low of -$16.4 million during Q4 2021.
  • Its 5-year average for Non Operating Income is -$151577.3, with a median of $237643.0 in 2022.
  • Within the past 5 years, the most significant YoY rise in BioRestorative Therapies' Non Operating Income was 1716819.3% (2023), while the steepest drop was 546249.97% (2023).
  • Quarter analysis of 5 years shows BioRestorative Therapies' Non Operating Income stood at -$16.4 million in 2021, then surged by 134.2% to $5.6 million in 2022, then crashed by 83.65% to $916688.0 in 2023, then increased by 14.98% to $1.1 million in 2024, then plummeted by 36.36% to $670734.0 in 2025.
  • Its Non Operating Income stands at $670734.0 for Q3 2025, versus $649024.0 for Q2 2025 and -$532265.0 for Q1 2025.